Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) stock rose 4.4% on Friday. The company’s highest price was $26.37 and the last traded price was $26.10. During the day, 316,822 shares traded, which was -78% compared to its average trading volume of 1,463,273 shares. The stock previously closed at $25.00.
Analyst rating changes
A number of equity research analysts have recently given their opinions on the stock. Piper Sandler lowered their target price on shares of Tandem Diabetes Care from $40.00 to $25.00 and gave the company an “overweight” rating in a research report on Thursday, November 2nd. Stifel Nicolaus increased their target price on shares of Tandem Diabetes Care from $17.00 to $24.00 and gave the company a “hold” rating in a report on Monday, February 5th. Finally, StockNews.com upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, nine have rated it with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $35.33.
Check out the latest report on Tandem Diabetes Care
Tandem Diabetes Care Price Performance
The stock has a market capitalization of $1.91 billion, a P/E ratio of -8.47 and a beta of 1.11. The company has a current ratio of 3.83, a quick ratio of 3.28 and a debt-to-equity ratio of 0.91. The company’s 50 day simple moving average is $25.82 and its 200 day simple moving average is $23.19.
Insider buying and selling
In related news, Director Dick Allen purchased 5,000 shares of the company’s stock in a transaction on Monday, November 27th. The shares were purchased at an average price of $18.96 per share, for a total transaction of $94,800.00. Following the acquisition, the director now owns 19,962 shares of the company’s stock, valued at approximately $378,479.52. The acquisition was disclosed in his SEC filing, available at this link. 2.50% of the shares are owned by insiders.
Hedge funds also pay attention to diabetes treatment tandem
Several hedge funds and other institutional investors have recently modified their positions in TNDM. RiverPark Advisors LLC bought a new position in shares of Tandem Diabetes Care in the 4th quarter valued at $27,000. The State of Wyoming grew its holdings in Tandem Diabetes Care by 45.8% in the 4th quarter. The State of Wyoming now owns 821 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 258 shares in the last quarter. Signaturefd LLC grew its position in Tandem Diabetes Care by 871.8% in the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after purchasing an additional 1,517 shares during the period. PNC Financial Services Group Inc. grew its position in Tandem Diabetes Care by 51.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock valued at $67,000 after purchasing an additional 1,099 shares during the period. Finally, GAMMA Investing LLC purchased a new position in Tandem Diabetes Care during the 4th quarter valued at $73,000.
Tandem Diabetes Care Company Profile
(Get Free Report)
Tandem Diabetes Care, Inc is a medical device company that designs, develops and commercializes a variety of products for people with insulin-dependent diabetes in the United States and internationally. The company’s flagship product is a pump platform consisting of the t:slim X2 insulin delivery system, t:slim X2 pump, 300-unit disposable insulin cartridge, and infusion set.
Related item
Receive daily Tandem Diabetes Care news and reviews – Enter your email address below to receive a concise, daily summary of the latest news and analyst ratings for Tandem Diabetes Care and related companies in MarketBeat.com’s free daily email newsletter.
